| RA | PKOA | P |
---|---|---|---|
Disease duration (years) | Â | Â | 0.005* |
 Range | 2–17 | 1.5–15 | |
 (Mean ± SD) | (6.94 ±2.98) | (4.69 ± 3.21) | |
Morning stiffness duration (min) |  |  | < 0.001* |
 Median (IQR) | 45 (20–60) | 15 (10–25) | |
VAS | Â | Â | 0.64 |
 Range | 0–9.5 | 0–8.5 | |
 (Mean ± SD) | (3.85±2.78) | (4.09 ± 2.35) | |
ESR mm/1st h |  |  | < 0.001* |
 Range | 10–90 | 8–17 | |
 Median (IQR) | 20 (13–32.25) | 12 (10–15) | |
CRP mg/dl |  |  | < 0.001* |
 Range | 2–33 | 2–5 | |
 Median (IQR) | 12 (5.5–15) | 4(2–5) | |
RF (positive) | 41/50 | 5/50 | < 0.001* |
RF titer IU/ml | Â | Â | Â |
 Range | 8–220 | – | |
 Mean ± SD | 48 (28–73.3) |  | |
Positive Anti-CCP titer U/ml | 31/50 | 0/50 | Â |
Anti-CCP Abs titer U/ml | 5–70 | – |  |
29.5 (17.5–39.5) |